Evidence map›Paper›PMID 40948580›Full record

ArticleMaterials today. Bio2025

Genetically engineered GSDME vesicle coated nanoparticle for immune activating and pyroptosis inducing synergetic therapy of fibrosarcoma.

Fenglin Miao, Zhao Wang, Qing Wang, Changsheng Zhou, Xiao Zhou, Jialiang Zheng, Yuan Ma, Zhenhang Lin, Yilai Gao, Ting Wu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The gasdermin family: from pyroptosis mechanisms to therapeutic targets.Signal transduction and targeted therapy · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fenglin MiaoCancer Research Center, School of Medicine, Xiamen University, Xiamen, 361102, China.
Zhao WangCancer Research Center, School of Medicine, Xiamen University, Xiamen, 361102, China.
Qing WangXiamen University Research Center of Retroperitoneal Tumor Committee of Oncology Society of Chinese Medical Association, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Changsheng ZhouCancer Research Center, School of Medicine, Xiamen University, Xiamen, 361102, China.
Xiao ZhouCancer Research Center, School of Medicine, Xiamen University, Xiamen, 361102, China.
Jialiang ZhengCancer Research Center, School of Medicine, Xiamen University, Xiamen, 361102, China.
Yuan MaCancer Research Center, School of Medicine, Xiamen University, Xiamen, 361102, China.
Zhenhang LinCancer Research Center, School of Medicine, Xiamen University, Xiamen, 361102, China.
Yilai GaoCancer Research Center, School of Medicine, Xiamen University, Xiamen, 361102, China.
Ting WuCancer Research Center, School of Medicine, Xiamen University, Xiamen, 361102, China.
Yong ZhangDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200030, China.
Jing GaoDepartment of Otorhinolaryngology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Wengang LiCancer Research Center, School of Medicine, Xiamen University, Xiamen, 361102, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibrosarcoma is a kind of highly malignant sarcoma with high recurrence rate after surgery and unsatisfying efficacy of radiotherapy and chemotherapy. Increasing the concentration of gasdermin in tumor cell to induce pyroptosis is a promising strategy to treat fibrosarcoma. However, the poor cytotoxic T lymphocytes (CTL) infiltration in tumor area limits the therapeutic effect with disabled positive feedback between pyroptosis and anti-tumor immunity. Induing tumor immunogenic cell death to activate anti-tumor immune and delivering gasdermin E (GSDME) to enhance tumor pyroptosis will rebuild the positive feedback. Hence, we proposed and constructed a genetically engineered GSDME vesicle coated nanoparticle (HV-FI) to achieve effective treatment of fibrosarcoma. First, the GSDME membrane-expressing tumor cells are constructed and the GSDME-displaying vesicles are extracted. Then the HV-FI is prepared by hybridizing red blood cell membranes and encapsulating ICG-loaded mesoporous Fe

Indexed as

Genetically engineered vesicleImmune activationPyroptosis inductionSynergy therapyTargeted delivery of GSDME

Identifiers

PMID40948580
PMCPMC12423601

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.